| Missense variants in DPYSL5 cause a neurodevelopmental disorder with corpus callosum agenesis and cerebellar abnormalities. | Missense variants in DPYSL5 cause a neurodevelopmental disorder with corpus callosum agenesis and cerebellar abnormalities.
Jeanne M, Demory H, Moutal A, Vuillaume ML, Blesson S, Thépault RA, Marouillat S, Halewa J, Maas SM, Motazacker MM, Mancini GMS, van Slegtenhorst MA, Andreou A, Cox H, Vogt J, Laufman J, Kostandyan N, Babikyan D, Hancarova M, Bendova S, Sedlacek Z, Aldinger KA, Sherr EH, Argilli E, England EM, Audebert-Bellanger S, Bonneau D, Colin E, Denommé-Pichon AS, Gilbert-Dussardier B, Isidor B, Küry S, Odent S, Redon R, Khanna R, Dobyns WB, Bézieau S, Honnorat J, Lohkamp B, Toutain A, Laumonnier F., Free PMC Article | 07/3/2021 |
| High CRMP5 expression is associated with prostate cancer. | miR-214-5p inhibits human prostate cancer proliferation and migration through regulating CRMP5.
Zheng C, Guo K, Chen B, Wen Y, Xu Y. | 03/21/2020 |
| Study describes the relevance of DRP5 during osteosarcoma development. DRP5 was upregulated in osteosarcoma specimens and cell lines and shown to function via the downstream MMPs. Inhibition of DRP5 suppressed the growth of cancer cells in vitro and in vivo, and high expression levels of DRP5 were associated with poor prognosis in osteosarcoma patients. | DRP5 is involved in cancer cell growth and predicts poor prognosis in human osteosarcoma.
Wang L, Liu W, Tang H, Xie X, Zou C, Wang Y, Gao Z, Yin J., Free PMC Article | 02/3/2018 |
| Our findings suggest that CRMP5 serves as a major mediator of Notch signaling and Akt activation by controlling the degradation of the Notch receptor, with implications for defining a biomarker signature in glioblastoma | CRMP5 Controls Glioblastoma Cell Proliferation and Survival through Notch-Dependent Signaling.
Moutal A, Honnorat J, Massoma P, Désormeaux P, Bertrand C, Malleval C, Watrin C, Chounlamountri N, Mayeur ME, Besançon R, Naudet N, Magadoux L, Khanna R, Ducray F, Meyronet D, Thomasset N. | 11/28/2015 |
| present study suggested that CRAM could be a clinical prognostic marker for patients with cervical cancer | High expression of CRAM correlates with poor prognosis in patients with cervical carcinoma.
Hou T, Liang D, Yang D, He J, Huang Y, Zhang Y., Free PMC Article | 12/20/2014 |
| study elucidates a novel regulatory mechanism that utilizes CRMP5-induced mitophagy to orchestrate proper dendrite outgrowth and neuronal function. | Collapsin response mediator protein 5 (CRMP5) induces mitophagy, thereby regulating mitochondrion numbers in dendrites.
Brot S, Auger C, Bentata R, Rogemond V, Ménigoz S, Chounlamountri N, Girard-Egrot A, Honnorat J, Moradi-Améli M., Free PMC Article | 03/29/2014 |
| identified residues that are crucial for determining the preference for hetero-oligomer or homo-oligomer formation. In spite of being the CRMP family member most closely related to dihydropyrimidinase, CRMP-5 does not have amidohydrolase activity. | Insights into the oligomerization of CRMPs: crystal structure of human collapsin response mediator protein 5.
Ponnusamy R, Lohkamp B. | 08/10/2013 |
| New CRMP5 isoform present in the nucleus is associated with Glioma. | Identification of a new CRMP5 isoform present in the nucleus of cancer cells and enhancing their proliferation.
Brot S, Malleval C, Benetollo C, Auger C, Meyronet D, Rogemond V, Honnorat J, Moradi-Améli M. | 04/20/2013 |
| patients with CV2/CRMP5-Ab and thymoma developed myasthenic syndrome more frequently | Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies.
Honnorat J, Cartalat-Carel S, Ricard D, Camdessanche JP, Carpentier AF, Rogemond V, Chapuis F, Aguera M, Decullier E, Duchemin AM, Graus F, Antoine JC., Free PMC Article | 01/21/2010 |
| findings point at CRMP5 as a novel marker for distinguishing between highly aggressive neuroendocrine carcinoma and the other lung cancers. | Extensive expression of collapsin response mediator protein 5 (CRMP5) is a specific marker of high-grade lung neuroendocrine carcinoma.
Meyronet D, Massoma P, Thivolet F, Chalabreysse L, Rogemond V, Schlama A, Honnorat J, Thomasset N. | 01/21/2010 |
| CRMP-5 autoimmune myelopathy and occult neoplasia are important considerations in patients with insidiously progressive myelopathy, especially with known cancer risk. | Autoimmune myelopathy associated with collapsin response-mediator protein-5 immunoglobulin G.
Keegan BM, Pittock SJ, Lennon VA. | 01/21/2010 |
| We describe a patient with optic neuropathy and vitritis as the only clinical manifestations of paraneoplastic optic neuropathy secondary to lung cancer marked by an extremely high titer of CRMP-5 antibody. | High-titer collapsin response-mediating protein-associated (CRMP-5) paraneoplastic optic neuropathy and Vitritis as the only clinical manifestations in a patient with small cell lung carcinoma.
Margolin E, Flint A, Trobe JD. | 01/21/2010 |
| CRMP-5-IgG defines a paraneoplastic ophthalmological entity of combined optic neuritis and retinitis with vitreous inflammatory cells. | Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG.
Cross SA, Salomao DR, Parisi JE, Kryzer TJ, Bradley EA, Mines JA, Lam BL, Lennon VA. | 01/21/2010 |